Sports
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventi
About this update from Inventiva Sa
[{"type":"image","alt":"INVENTIVA","displaySize":"","headline":null,"caption":"INVENTIVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IFR.Gz27ItPSlaHquTiPVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123","width":300,"height":142}},"lazy":false},{"type":"text","content":"Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the half-year report of its liquidity contract with Kepler Cheuvreux.","length":432,"tagName":"p"},{"type":"text","content":"Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of 31 December 2025:","length":158,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cash: € 526,751.56","length":18,"tagName":"p"}]},{"val":[{"type":"text","content":"Number of shares: 58,515","length":24,"tagName":"p"}]},{"val":[{"type":"text","content":"Number of executions on buy side on semester: 2,332","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"Number of executions on sell side on semester: 2,741","length":52,"tagName":"p"}]},{"val":[{"type":"text","content":"Traded volume on buy side on semester: 550,198 shares for € 2,093,559.19","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Traded volume on sell side on semester: 576,215 shares for € 2,189,327.66","length":73,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":290,"olType":false},{"type":"text","content":"At the last half-year report as of 30 June 2025 the following resources were available in the liquidity account:","length":112,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cash: € 428,212.57","length":18,"tagName":"p"}]},{"val":[{"type":"text","content":"Number of shares: 84,532","length":24,"tagName":"p"}]},{"val":[{"type":"text","content":"Number of executi...